|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marty Makary resigned from the FDA on Tuesday, following reports that President Donald Trump had signed off on a plan to fire him. Makary’s final weeks were marked by pressure on a range of issues, from flavored vapes to drug approval decisions. Drew Armstrong dissected Makary’s tumultuous tenure in a Post-Hoc piece here. Tomorrow, he and senior reporter Max
Bayer will discuss where the agency goes next at the Financial Times’ US Pharma and Biotech Summit. Click here for details on how to tune in. |
|
|
|
Nicole DeFeudis |
Editor, Endpoints News
@Nicole_DeFeudis
|
|
|
|
 |
|
Marty Makary (Jose Luis Magana/AP Images) |
|
|
|
by Max Bayer
|
FDA Commissioner Marty Makary has resigned after his job status hung in the balance for days. President Donald Trump confirmed the news Tuesday in a... | |
|
|
|
|
|
|
by Drew Armstrong
|
Marty Makary never stood a chance. Over the last few days, the now-former FDA commissioner had been left to twist in the wind, after headlines... | |
|
|
|
|
|
|
by Max Gelman
|
There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase... | |
|
|
|
 |
|
Harith Rajagopalan, Fractyl Health CEO |
|
|
|
by Ryan Cross
|
Drug developers are racing to make gene therapiesthat could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just... | |
|
|
|
|
|
|
by Anna Brown
|
The Critical Medicines Act reached its next milestone on Tuesday, after the European Parliament and the Council provisionally voted it through. The proposed regulation aims... | |
|
|
|
|
|
|
|
Worldwide made. Thanks for reading.
|
|
|
|
|
|
|
|
